KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) EBITDA (2016 - 2025)

Historic EBITDA for Exact Sciences (EXAS) over the last 17 years, with Q3 2025 value amounting to -$25.5 million.

  • Exact Sciences' EBITDA rose 3516.99% to -$25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 31635.43%. This contributed to the annual value of -$1.0 billion for FY2024, which is 38774.16% down from last year.
  • Latest data reveals that Exact Sciences reported EBITDA of -$25.5 million as of Q3 2025, which was up 3516.99% from -$2.1 million recorded in Q2 2025.
  • In the past 5 years, Exact Sciences' EBITDA registered a high of $6.8 million during Q3 2023, and its lowest value of -$876.4 million during Q4 2024.
  • For the 5-year period, Exact Sciences' EBITDA averaged around -$149.3 million, with its median value being -$106.7 million (2024).
  • In the last 5 years, Exact Sciences' EBITDA surged by 10496.1% in 2023 and then crashed by 119177.19% in 2024.
  • Over the past 5 years, Exact Sciences' EBITDA (Quarter) stood at -$221.4 million in 2021, then surged by 46.32% to -$118.9 million in 2022, then skyrocketed by 42.93% to -$67.8 million in 2023, then crashed by 1191.77% to -$876.4 million in 2024, then surged by 97.09% to -$25.5 million in 2025.
  • Its EBITDA was -$25.5 million in Q3 2025, compared to -$2.1 million in Q2 2025 and -$96.0 million in Q1 2025.